EU Approves GlaxoSmithKline and Genmab's Leukemia Treatment
July 03 2014 - 10:52AM
Dow Jones News
By Rory Gallivan
LONDON--The European Union has approved GlaxoSmithKline PLC's
(GSK.LN) and Genmab A/S's (GEN.KO) leukemia treatment Arzerra to be
used in patients unable to use an alternative drug.
The companies said Thursday that the EU has given marketing
permission for Arzerra "as first-line treatment for chronic
lymphocytic leukemia in combination with chlorambucil or
bendamustine for patients ineligible for fludarabine-based
therapy."
Jan van de Winkel, chief executive of Genmab said: "This is
another important milestone and we look forward to a successful
launch under this new indication of the drug in Europe in the
coming months."
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024